Chemotherapy + Hepatic Arterial Infusion for Colorectal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
RATIONALE: Hepatic arterial infusion uses a catheter to carry tumor-killing substances directly into the liver. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving floxuridine and dexamethasone directly into the arteries around the tumor together with combination chemotherapy may kill more tumor cells.PURPOSE: This phase II trial is studying how well hepatic arterial infusion with floxuridine and dexamethasone works when given together with combination chemotherapy in treating patients with colorectal cancer that has spread to the liver.
Who Is on the Research Team?
Michael D'Angelica, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Nancy E. Kemeny, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with colorectal cancer that has spread to the liver, who may have had prior chemotherapy but no hepatic arterial infusion or certain other treatments. They should not have widespread disease outside the liver, significant blood or heart conditions, active infections, or be pregnant. Adequate organ function and a good performance status are required.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive hepatic arterial infusion therapy with floxuridine and dexamethasone, combined with systemic chemotherapy. Courses repeat every 4 weeks.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Follow-up occurs every 3 months for 2 years, every 4 months for 3 years, and then annually.
What Are the Treatments Tested in This Trial?
Interventions
- Dexamethasone
- Floxuridine
- Fluorouracil
- Hepatic Arterial Infusion
- Irinotecan Hydrochloride
- Leucovorin Calcium
- Oxaliplatin
Dexamethasone is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator